Pharma, FDA still lagging in post-marketing safety research

The good news: Drugmakers are wrapping up more post-marketing safety studies, now that the FDA can crack the whip. More good news: Companies got to work on a bigger proportion of the studies required. The bad news: More than 40% of required studies still haven't begun, and the percentage of completions is still quite low. Report

Suggested Articles

Solid Bio fixed the manufacturing issue that led to a partial clinical hold on its DMD trial, but a full hold remains.

Commissioner Scott Gottlieb has laid out the reasons why he thinks the FDA needs a double-digit budget bump.

GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.